Low-dose IL-2 reduces IL-21+ T cell frequency and induces anti-inflammatory gene expression in type 1 diabetes
Low-dose interleukin-2 is showing promise in the treatment of several autoimmune inflammatory diseases. Here authors map the trajectory of cellular and transcriptional changes in type 1 diabetes patients receiving an interval dosing interleukin-2 regimen, which shows an anti-inflammatory gene expres...
Hlavní autoři: | , , , , , , , , , , , , , , |
---|---|
Médium: | Článek |
Jazyk: | English |
Vydáno: |
Nature Portfolio
2022-11-01
|
Edice: | Nature Communications |
On-line přístup: | https://doi.org/10.1038/s41467-022-34162-3 |